Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Olanzapine Viatris (previously Olanzapine Mylan)

Olanzapine Viatris 2.5 mg film-coated tablets Olanzapine Viatris 5 mg film-coated tablets Olanzapine Viatris 7.5 mg film-coated tablets Olanzapine Viatris 10 mg film-coated tablets Olanzapine Viatris 15 mg film-coated tablets Olanzapine Viatris 20 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 9–10

HOS-120675 · Präparat HOS-095185

9  including constipation and dry mouth Hepatobiliary disorders Transient, Hepatitis (including asymptomatic hepatocellular, elevations of hepatic cholestatic or mixed aminotransferases liver injury)11 (ALT, AST), especially in early treatment (see section 4.4) Skin and subcutaneous tissue disorders Rash Photosensitivity Drug Reaction reaction with Eosinophilia Alopecia and Systemic Symptoms (DRESS) Musculoskeletal and connective tissue disorders Arthralgia9 Rhabdomyolysis11 Renal and urinary disorders Urinary incontinence, urinary retention Urinary hesitation11 Pregnancy, puerperium and perinatal conditions Drug withdrawal syndrome neonatal (see section 4.6) Reproductive system and breast disorders Erectile dysfunction in Amenorrhea Priapism12 males Breast enlargement Decreased libido in Galactorrhea in females males and females Gynaecomastia/breast enlargement in males General disorders and administration site conditions Asthenia Fatigue Oedema Pyrexia10 Investigations Elevated Increased alkaline Increased total bilirubin plasma phosphatase10 prolactin High creatine levels8 phosphokinase11 High Gamma Glutamyltransferase10 High Uric Acid10

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.